Tech Company Financing Transactions
Cereius Funding Round
On 7/26/2018, Cereius received $6.8 million in Series A funding from BioInnovation, North Carolina Biotechnology Center and private investors.
Transaction Overview
Company Name
Announced On
7/26/2018
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$6,750,000
Round
Series A
Investors
BioInnovation (Lead Investor) (Eric Linsley)
Proceeds Purpose
We are actively advancing our own portfolio of radiotherapies and imaging agents based on our technology. We have also initiated discussions with potential partners who have explored novel targeting agents, like antibodies or camelids (VHHs), and would benefit from our novel radiolabeling technology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
701 W Main St. 200
Durham, NC 27701
USA
Durham, NC 27701
USA
Phone
Undisclosed
Website
Email Address
Overview
Cereius' intellectual property includes next-generation radiolabeling chemistries. The chemistries can employ a variety of medically advantageous radionuclides to either enhance the detection sensitivity of diagnostic imaging or to improve the therapeutic index of targeted therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ed Field
Co-Founder
Kim Blackwell
Co-Founder
Michael Zalutsky
VP - R & D
Jeffrey Schaal
Browse more venture capital transactions:
Prev: 7/26/2018: Triad Semiconductor venture capital transaction
Next: 7/26/2018: ColdQuanta venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs